Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry

Real‐world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous.

[1]  R. Zukov,et al.  COVID-19 in Patients With Renal Cell Carcinoma in the Russian Federation , 2020, Clinical Genitourinary Cancer.

[2]  A. Sasse,et al.  First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis. , 2020, Clinical genitourinary cancer.

[3]  C. Porta,et al.  Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). , 2020 .

[4]  F. Saad,et al.  Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities , 2020, Cancer Causes & Control.

[5]  Pengxiang Li,et al.  Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma. , 2019, JAMA network open.

[6]  A. Shteynshlyuger.  Many Elderly Patients With Stage IV Metastatic Renal Cell Carcinoma May Benefit From More-Aggressive Treatment. , 2019, JAMA network open.

[7]  B. Escudier,et al.  Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study. , 2019, Journal of Clinical Oncology.

[8]  J. Joo,et al.  Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Regi , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[9]  C. Porta,et al.  Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme , 2018, BJU international.

[10]  A. Kapoor,et al.  Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting. , 2018, Current oncology.

[11]  M. Hubbe,et al.  Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry , 2018, AntiCancer Research.

[12]  A. Poprach,et al.  Treatment sequences in metastatic renal cell carcinoma: Efficacy results from the Czech registry (RENIS). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  T. Choueiri,et al.  Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil , 2017, Journal of global oncology.

[14]  N. Agarwal,et al.  Real‐World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER–Medicare Database Analysis , 2017, Clinical genitourinary cancer.

[15]  S. Menon,et al.  Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India , 2017, Clinical Genitourinary Cancer.

[16]  A. Poprach,et al.  Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice , 2016, Drugs & Aging.

[17]  T. Reinert,et al.  Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience , 2016, International braz j urol : official journal of the Brazilian Society of Urology.

[18]  David C. Smith,et al.  Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. , 2016 .

[19]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.